Λ		ורו		
A	IJ	R	U	V

Half Year Report 2023

Adrigo Small & Midcap L/S

Important Notice
Historic yields are no guarantee for future yields. Fund units can go up or down in value, and investors may not get back the amount invested. Key investor information documents and prospectuses are available at www.adrigo.se.

This Half Year Report is a translation from the original Swedish version, the latter being the official version. In the case of discrepancies between the English translation and the Swedish original, the original takes precedence.

## Contents

General market comment	4
Adrigo Small & Midcap L/S	5

### General market comment

Global stock markets performed strongly in the first half of 2023, with the MSCI World rising 15.5%. The Nasdaq and S&P 500 rose 32.2% and 16.9% respectively. In Europe, the EURO STOXX 50 closed up 19.2% for the period. The Nordic large-cap index OMX N40 rose 5.6%. Development was particularly weak in Finland, where the index fell 3.5%. Small companies underperformed large companies in both the US and the Nordic countries. This trend indicates uncertainty among the management community, where the risk appetite has been relatively low, and the most liquid shares have been favoured. A change could be discerned in June when small caps performed well, in line with large caps.

The expected recovery in China did not materialise and we saw a broad decline in various economic activity indicators. The Chinese stock market fell around 5%. The Chinese government has historically shown an impressive ability to stimulate the economy and, at the time of writing, there are signs that this will now happen.

Price increases, to compensate for increased costs, have remained in focus. Overall, customer acceptance has been good and the results for the first quarter exceeded expectations in most cases. Interest rates were also in focus, and we have seen substantial increases from the world's central banks.

The problems in portions of the banking sector, in particular SVB and Credit Suisse, also affected the perception of Nordic banks. The Swedish banks' share prices were even more affected by the property market, where several players proved to be overly leveraged, as interest rates continued to rise while the assets, i.e., real estate, fell in value due to higher yield requirements.

The price of oil (Brent) fell by 12% during the period, representing a weakening of 35% since the middle of 2022. As a result, OPEC unexpectedly announced production cuts in April.

From the second quarter reports, we can note that the long-awaited decline in demand can now also be discerned among companies.

Note: The information in this report represents historical data and is not an indication of future performance.

#### Management report

The Fund decreased by 10% in the first half of the year (in SEK). The net asset value was 302m SEK as of 30 June 2023, to be compared to 507m SEK as of 31 December 2022. Net outflows during the period amounted to 166m SEK.

The first quarter started positively with an increase of 2.5% followed by weaker performance in February and March. A write-down of an unlisted asset had a negative impact of 1.6% in March. The second quarter also started well with the Fund rising by 4.1% in April. However, returns in May and June were negative. The Fund's holdings in Online Brands and Pierce had a significant negative impact on returns. During the first half of the year, these two holdings fell by 54% and 24% respectively. In the case of Online Brands, nothing has fundamentally changed and our confidence in the management and business concept remains.. As for Pierce, we note that the market has been weaker than we expected. However, the valuation is extremely cautious, with the value of cash and inventory exceeding the market capitalisation.

The best contributor in 2022, Bonesupport, also contributed the most to the return in 1H 2023. The fund has invested in the company since the end of 2017, and we see continued good potential. During the spring, we have seen how the core product, Cerament G, which was launched in the US in the fourth quarter of 2022, has grown significantly. Through the Cerament G and an expanded customer base, sales in the US grew by 100% during the period.

We have owned shares in Kahoot since 2018 and sold our entire holding last year. At the beginning of 2023, we felt that investors' expectations were too pessimistic, and the share price had fallen 90% since its peak. We therefore chose to reinvest, which proved successful. Since then, the company has delivered as expected and the share rose by 51% during the first half.

Other holdings that made good positive contributions to the return are Lundbeck, Attendo, Momentum Group and Initiator Pharma.

New investments in the first half of the year include Himalaya Shipping, Nordic Semiconductor and BHG.

### The Fund's risk exposure

During the period, the Fund was mainly exposed to the following risks: market risk, currency risk and liquidity risk. These risks are usually higher, often reflected in higher price volatility, compared to funds that invest their assets in geographies with larger stock markets and large capitalisation companies. The Fund has been exposed to market risk through movements in market prices. The Fund's returns have been exposed to exchange rate fluctuations as the Fund's assets consist partly of securities denominated in currencies other than the Fund's base currency. Liquidity risk is higher than for a fund investing in large companies. This means that it may be difficult to sell holdings in the market without negative effects on the price. In addition, the Fund's liquidity needs may arise from collateral requirements for the short positions taken by the Fund. The Fund takes long and short positions which, depending on the prevailing market dynamics, may lead to a reduction in risk but also to periods of increased risk.

### Objective

Adrigo Small & Midcap L/S is a hedge fund focusing on investments in Nordic equities in the Small & Midcap segment.

Adrigo Small & Midcap L/S is a "Specialfond" according to the Swedish Managers of Alternative Investment Funds Act (2013:561) ("LAIF"), which means that there are fewer investment restrictions compared to a standard mutual fund. The Fund Articles, which are incorporated in the Information Memorandum, have been approved by the Swedish Financial Supervisory Authority, which also supervises the Fund.

### Investment Policy of the Fund

The Fund's main investment focus is on listed financial instruments in the Nordic countries, primarily equities and equity related instruments. The Fund may to a lesser extent, but up to 10 % of the Fund's value, invest in unlisted financial instruments issued by companies registered in the Nordic countries.

The Fund may invest in the asset class transferable securities (shares), money market instruments, derivatives, fund units and accounts with credit institutions.

The Fund may sometimes have high liquidity, it may borrow to achieve leverage and it may use short selling strategies, i.e. to sell shares that have been borrowed.

Note: All performance figures in the management report are in SEK unless otherwise stated.

 $<sup>{}^*\, \</sup>text{The annual report and half year report of the Fund are available at the registered address of the Management Company.}$ 

### Key figures <sup>1</sup>

Total return	2023 H1	2022	2021	2020	2019	2018	2017
class A SEK	-10%	-5%	-5%	44%	14.09%	8.69%	6.14%
class C SEK	-10%	*10%	-	-	-	-	-
Benchmark <sup>2</sup>	-	-	-	-	-	-	-
Net asset value (in '000s SEK)							
class A SEK	122 458	193 296	304 584	496 968	429 706	248 434	141 020
class C SEK	179 622	313 249	_	-	_	-	_
Number of units (without							
decimal)							
class A SEK	796 093	1 135 581	1 697 976	2 630 205	3 264 859	1 917 699	1 250 792
class C SEK	95 225	150 073	-	-	-	-	-
Unit value (in SEK)							
class A SEK	153.82	170.22	179.38	188.95	131.61	115.36	106.14
class C SEK	1 886.27	2 087.29	_	-	_	-	_
Dividend per unit (in SEK)							
class A SEK	-	-	_	-	_	-	-
class C SEK	-	-	_	-	_	-	-

Balance sheet (in '000s SEK)	30-06-2023	2022
Assets		
Transferable securities	418 306	738 266
Money market instruments	0	0
OTC derivative instruments with positive market value	0	0
Other derivative instruments with positive market value	443	4 740
Total financial instruments with positive market value (Note 1)	418 749	743 006
Bank deposits and other cash equivalents	25 948	24 127
Prepaid expenses and accrued income	1 011	0
Other assets	44 660	41 505
<u>Total assets</u>	490 368	808 638
<u>Liabilities</u> Other financial instruments with negative market		
value	-162 907	-266 375
<u>Total financial instruments with negative market value</u>	-162 907	-266 375
Accrued expenses and pre-paid income	-317	-504
Other liabilities	-25 064	-35 214
Total liabilities	-188 288	-302 093
Net asset value	302 080	506 545

Management company	East Capital Asset Management S.A.
Launch date	1 November 2017 (class A SEK)
	2 May 2022 (class C SEK)
Quotation/trade	Monthly
Dividend	No (class A SEK and class C SEK)
Management fee	1% (class A SEK and class C SEK)
Subscription fee	5% (class A SEK)
	0% (class C SEK)
Redemption fee	0.2% (class A SEK)
	0% (class C SEK)
Domicile	Sweden
Minimum investment	Minimum initial investment 50.000 SEK (class A SEK) thereafter the minimum additional investment: 1.000 SEK (class A SEK)
	Minimum initial investment 100.000 SEK (class C SEK)
NAV currency	SEK
ISIN	SE0010440735 (class A SEK)
	SE0017133366 (class C SEK)

### Note 1: Financial instruments

See the detail of the financial instruments pages 7-9 "Holdings and positions"  $\,$ 

Note 2: Collateral (in '000s SEK)	30-06-2023	2022
Paid collateral for OTC derivative instruments	31 859	31 899
Other paid collateral	208 491	448 196

Notes: Past performance cannot be used as an indicator for current or future performance. The performance data do not take into account the commission and fees generated each time fund units are issued and purchased.

The reporting principles are available at the end of this report.

<sup>\*</sup> Total return for the period May – December 2022.

 $<sup>^{\</sup>mbox{\tiny 1}}$  Based on the end of year NAV.

 $<sup>^{\</sup>rm 2}$  The fund does not use a benchmark.

# Holdings and positions (in SEK) as at 30 June 2023

Online Brands Nordic AB Perce Group AB Addrech AB Addrech AB Addrech AB Afa Laval A	Issuer	Security	Number/Nominal	Market value	% of total net assets
Retailers	Transferable securities listed for trading on a	a regulated market or the equivalent outside	e of the EEA		
Online Brands Nordic AB Colline Brands Nordic AB (Collateral) 302 149 3 973 259 Chille Brands Nordic AB 1 1495 367 1196 540 776 1964 1776 1780 1780 1780 1780 1780 1780 1780 1780	Shares				
Industrial Goods	Online Brands Nordic AB Online Brands Nordic AB Pierce Group AB Pierce Group AB	Online Brands Nordic AB Pierce Group AB (Collateral)	1 495 367 739 064	19 664 076 5 069 979 24 031 883	1.32 6.51 1.68 7.96
Addrech AB A Addrech AB B Reg	Total Retailers			52 739 197	17.47
Affa Laval AB   Alfa Laval AB   -45 0000   -17 685 000   -	Industrial Goods				
Indutrade AB   Nice Industrier AB   Nice Industrier AB   1-300 00   1-12 145 000   1-13 312 000   1-17 000		<del>_</del>			-3.89
Nibe Industrier AB	Alfa Laval AB	Alfa Laval AB	-45 000	-17 685 000	-5.85
Trelleborg AB					-4.02
Total Industrial Goods	Nibe Industrier AB	Nibe Industrier AB		-13 312 000	-4.41
Food & Beverages	Trelleborg AB	Trelleborg AB B	-45 000	-11 763 000	-3.89
AKK AB Reg	Total Industrial Goods			-66 645 000	-22.06
Total Food & Beverages   File   Fil	Food & Beverages				
Technology Equipment   Kitron ASA   Kitron ASA   -120 000   -5 271 417   -5 271 4		AAK AB Reg	-36 448		-2.45
Kitron ASA	Total Food & Beverages			-7 391 654	-2.45
Automobiles & Auto Parts   Dometic Group AB   Dometic Group AB (Collateral)   300 000   21 300 000   21 300 000   31 300					
Automobiles & Auto Parts		Kitron ASA	-120 000		-1.75
Dometic Group AB	Total Technology Equipment			-5 271 417	-1.75
Energy - Fossil Fuels   Borr Drilling Ltd   Borr Drilling Ltd   150 000   11 907 593   1		D C AD (C )	200.000	24 200 000	7.05
Borr Drilling Ltd	•	Dometic Group AB (Collateral)	300 000		7.05 <b>7.05</b>
Borr Drilling Ltd					
Dolphin Drilling AS   Subsea 7 SA   Subsea		Ross Dailling Ltd	150,000	11 007 503	2.04
Subsea 7 SA	<del>-</del>	<del>-</del>			3.94
Healthcare Services & Equipment	•				10.27
Ambu AS Arjo AB B Reg 300 000 11 724 0000 Bioservo Technology AB Bioservo Technology AB (Collateral) 842 944 487 222 Bioservo Technology AB Bioservo Technology AB (Collateral) 842 944 487 222 Bioservo Technology AB Bioservo Technology AB 1 740 915 1 006 249 Bioservo Technology AB Bioservo Technology AB Uts 1 722 572 2 635 535 Getinge AB Getinge AB Getinge AB B (Collateral) 10 000 1 889 500 Getinge AB Getinge AB B (Collateral) 50 000 9 447 500 OssDsign AB OssDsign AB Reg (Collateral) 30 0740 1 710 515 OssDsign AB OssDsign AB Reg (Collateral) 2736 929 13 739 384 Vitrolife AB Witrolife AB Reg 2 736 929 13 739 384 Vitrolife AB Witrolife AB Reg 2 5000 5 235 000 Total Healthcare Services & Equipment 41 502 988 1:  Food & Drug Retailing Axfood AB Axfood AB -50 000 -11 410 000 -71 41		Subsea / SA	-83 252		-3.72 <b>10.49</b>
Ambu AS Arjo AB Bearer Reg Arjo AB Arjo AB Arjo AB B Reg 300 000 11 724 0000 Bioservo Technology AB Bioservo Tec					
Arjo AB		Ambu AS B Bearer Reg	-36.046	-6 371 917	-2.11
Bioservo Technology AB   T22 572   2 635 535		5			3.88
Bioservo Technology AB   1722 572   2 635 535     Getinge AB   Getinge AB   Getinge AB   Gollateral)   10 000   1 889 500     Getinge AB   Getinge AB   Gollateral)   50 000   9 447 500     OssDsign AB   OssDsign AB Reg (Collateral)   340 740   1 710 515     OssDsign AB   OssDsign AB Reg   2 736 929   13 739 384     Vitrolife AB   Vitrolife AB Reg   25 000   5 235 000     Total Healthcare Services & Equipment   41 502 988   1:    Food & Drug Retailing					0.16
Bioservo Technology AB					0.10
Getinge AB   Getinge AB B (Collateral)   10 000   1 889 500   Getinge AB B (Getinge AB B (Collateral)   50 000   9 447 500   9 447 500   0 5000   9 447 500   0 5000   9 447 500   0 5000   9 447 500   0 5000   9 447 500   0 5000   9 447 500   0 5000   9 447 500   0 5000   9 447 500   0 500	<del>-</del> ,	<del>-</del> ,			0.87
Getinge AB   Getinge AB   Collateral)   50 000   9 447 500     OssDsign AB   OssDsign AB Reg (Collateral)   340 740   1 710 515     OssDsign AB   OssDsign AB Reg (Collateral)   340 740   1 710 515     OssDsign AB   OssDsign AB Reg   2 736 929   13 739 384     Vitrolife AB   Vitrolife AB   Vitrolife AB Reg   25 000   5 235 000     Total Healthcare Services & Equipment   41 502 988   1:     Food & Drug Retailing	3,				0.63
OssDsign AB         OssDsign AB Reg (Collateral)         340 740         1 710 515           OssDsign AB         OssDsign AB Reg         2 736 929         13 739 384           Vitrolife AB         Vitrolife AB Reg         25 000         5 235 000           Total Healthcare Services & Equipment         41 502 988         1:           Food & Drug Retailing           Axfood AB         -50 000         -11 410 000         -7           Total Food & Drug Retailing           Arla Plast AB         Axfood AB         -50 000         -11 410 000         -7           Chemicals           Arla Plast AB         Arla Plast AB (Collateral)         200 000         6 680 000         After Plast AB         41 776 1525         After Plast AB         41 776 1525         41 40 000         11 468 812         41 40 88 12         41 40 88 12         41 40 88 12         41 40 88 12         41 40 88 12         42 41 40 600         41 40 600         41 40 600         41 40 600         41 50 200         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 000         41 6 00		- '			3.13
OssDsign AB         OssDsign AB Reg         2 736 929         13 739 384           Vitrolife AB         Vitrolife AB Reg         25 000         5 235 000           Total Healthcare Services & Equipment         41 502 988         13           Food & Drug Retailing           Axfood AB         -50 000         -11 410 000         -17           Total Food & Drug Retailing         -11 410 000         -11 410 000         -11 410 000         -11 410 000           Chemicals         Arla Plast AB         Arla Plast AB (Collateral)         200 000         6 680 000         6 680 000         -11 41					0.57
Vitrolife AB         Vitrolife AB Reg         25 000         5 235 000           Total Healthcare Services & Equipment         41 502 988         13           Food & Drug Retailing	<del>-</del>	5 5 ,			4.55
Total Healthcare Services & Equipment					1.73
Axfood AB		Vittolile Ab Reg	23 000		13.74
Axfood AB	Food & Drug Potailing				
Total Food & Drug Retailing		Axfood AB	-50 000	-11 410 000	-3.78
Arla Plast AB Arla Plast AB (Collateral) 200 000 6 680 000 Arla Plast AB Arla Plast AB Arla Plast AB 232 381 7 761 525 Yara Intl ASA Yara Intl ASA (Collateral) 30 000 11 468 812 25 910 337 8  Pharmaceuticals & Medical Research  Bonesupport Hg AB Bonesupport Hg AB Reg (Collateral) 160 000 20 416 000 Calliditas Therapeutics AB Calliditas Therapeutics AB (Collateral) 140 000 12 138 000 Calliditas Therapeutics AB Calliditas Therapeutics AB 10 472 907 922 Camurus AB Camurus AB (Collateral) 80 000 22 288 000 Lidds AB Lidds AB (Collateral) 129 285 62 574 Lidds AB Lidds AB Lidds AB Lidds AB Lidds AB 1 627 621 787 769		AMIOGU ALE	30 000		-3.78
Arla Plast AB Yara Intl ASA Yara Intl ASA (Collateral) 30 000 11 468 812  Total Chemicals 25 910 337 8  Pharmaceuticals & Medical Research  Bonesupport Hg AB Bonesupport Hg AB Reg (Collateral) 160 000 20 416 000 Calliditas Therapeutics AB Calliditas Therapeutics AB (Collateral) 140 000 12 138 000 Calliditas Therapeutics AB Calliditas Therapeutics AB (Collateral) 10 472 907 922 Camurus AB Camurus AB (Collateral) 80 000 22 288 000 Lidds AB Lidds AB (Collateral) 129 285 62 574 Lidds AB Lidds AB (Lidds AB (Collateral) 1 627 621 787 769		A L DL LAD (C. II :	200 5	6 600 05-	
Yara Intl ASA       Yara Intl ASA (Collateral)       30 000       11 468 812       25 910 337       8         Pharmaceuticals & Medical Research         Bonesupport Hg AB       Bonesupport Hg AB Reg (Collateral)       160 000       20 416 00		` ,			2.21 2.57
Pharmaceuticals & Medical Research  Bonesupport Hg AB Bonesupport Hg AB Reg (Collateral) 160 000 20 416 000 20 416 000 20 416 000 12 138 000 20 416 000 12 138 000 20 416 000 20					
Bonesupport Hg AB Bonesupport Hg AB Reg (Collateral) 160 000 20 416 000 Calliditas Therapeutics AB Calliditas Therapeutics AB (Collateral) 140 000 12 138 000 Calliditas Therapeutics AB Calliditas Therapeutics AB 10 472 907 922 Camurus AB Camurus AB (Collateral) 80 000 22 288 000 Lidds AB Lidds AB (Collateral) 129 285 62 574 Lidds AB Lidds AB Lidds AB 1 627 621 787 769		fara IIIti ASA (Collateral)	30 000		3.80 <b>8.58</b>
Bonesupport Hg AB         Bonesupport Hg AB Reg (Collateral)         160 000         20 416 000           Calliditas Therapeutics AB         Calliditas Therapeutics AB (Collateral)         140 000         12 138 000           Calliditas Therapeutics AB         Calliditas Therapeutics AB         10 472         907 922           Camurus AB         Camurus AB (Collateral)         80 000         22 288 000           Lidds AB         Lidds AB (Collateral)         129 285         62 574           Lidds AB         Lidds AB         1 627 621         787 769	Pharmaceuticals & Medical Pessarch				
Calliditas Therapeutics AB Calliditas Therapeutics AB (Collateral) 140 000 12 138 000 Calliditas Therapeutics AB Calliditas Therapeutics AB 10 472 907 922 Camurus AB Camurus AB (Collateral) 80 000 22 288 000 Lidds AB Lidds AB (Collateral) 129 285 62 574 Lidds AB Lidds AB 1 627 621 787 769		Bonesupport Hg AB Reg (Collateral)	160 000	20 416 000	6.76
Calliditas Therapeutics AB       Calliditas Therapeutics AB       10 472       907 922         Camurus AB       Camurus AB (Collateral)       80 000       22 288 000         Lidds AB       Lidds AB (Collateral)       129 285       62 574         Lidds AB       Lidds AB       1 627 621       787 769	· · · -	,			4.02
Camurus AB       Camurus AB (Collateral)       80 000       22 288 000         Lidds AB       Lidds AB (Collateral)       129 285       62 574         Lidds AB       Lidds AB       1 627 621       787 769	·				0.30
Lidds AB         Lidds AB (Collateral)         129 285         62 574           Lidds AB         Lidds AB         1 627 621         787 769	·				7.38
Lidds AB Lidds AB 1 627 621 787 769					0.02
		· · · · · · · · · · · · · · · · · · ·			0.26
TOTAL PHARMACEUTICALS & MEGICAL RESEARCH 56 600 265 18	Total Pharmaceuticals & Medical Research			56 600 265	18.74

# Holdings and positions (in SEK) as at 30 June 2023

Issuer	Security	Number/Nominal	Market value	% of total net assets
Industrial & Commercial Services Frontline Plc Total Industrial & Commercial Services	Frontline Ltd (Collateral)	150 000	23 373 379 <b>23 373 379</b>	7.74 <b>7.74</b>
Transportation				
AP Moeller Maersk AS	AP Moeller Maersk AS B	-500	-9 479 814	-3.14
DSV A/S Golden Ocean Group Ltd	DSV A/S Golden Ocean Group Ltd (Collateral)	-5 000 183 826	-11 344 111 14 982 224	-3.76 4.96
Himalaya Shipping Ltd	Himalaya Shipping Ltd	270 034	15 634 656	5.18
Hoegh Autoliners ASA  Total Transportation	Hoegh Autoliners ASA	-125 000	-7 672 353 <b>2 120 602</b>	-2.54 <b>0.70</b>
Software & IT Services				
BHG Group AB	BHG Group AB Reg (Collateral)	617 149	9 263 406	3.07
Embracer Group AB	Embracer Group AB	-250 000	-6 740 000	-2.23
Embracer Group AB	Embracer Group AB (Collateral)	256 396	6 912 436	2.29
Fortnox AB	Fortnox AB	-227 510	-14 487 837	-4.80
Howwe Technologies AB Kahoot AS	Howwe Technologies AB Kahoot AS Reg (Collateral)	885 658 500 000	7 501 523 14 767 231	2.48 4.89
Opter AB	Opter AB (Collateral)	120 000	8 280 000	2.74
Opter AB	Opter AB	174 025	12 007 725	3.97
Sinch AB	Sinch AB (Collateral)	500 000	12 175 000	4.03
Sinch AB  Total Software & IT Services	Sinch AB	-200 000	-4 870 000 <b>44 809 484</b>	-1.61 <b>14.83</b>
Total shares			209 343 839	69.30
Total transferable securities listed for trading	on a regulated market or the equivalent of	outside of the EEA	209 343 839	69.30
Pharmaceuticals & Medical Research Initiator Pharma AS Initiator Pharma AS Total Pharmaceuticals & Medical Research	Initiator Pharma AS Initiator Pharma AS (Collateral)	3 430 002 254 648	24 353 014 1 808 001 <b>26 161 015</b>	8.06 0.60 <b>8.66</b>
Total shares			26 161 015	8.66
Total transferable securities subject to regular public	ar trading on another market which is regu	lated and open to the	26 161 015	8.66
Other financial instruments				
Shares				
Banking & Investment Services				
Webrock Ventures AB  Total Banking & Investment Services	Webrock Ventures AB	189 759	9 867 468 <b>9 867 468</b>	3.27 <b>3.27</b>
Software & IT Services				
Fishbrain SA G-Loot Global Esports AB Total Software & IT Services	Fishbrain SA G-Loot Global Esports AB Reg	50 000 20 618	7 531 643 412 360 <b>7 944 003</b>	2.49 0.14 <b>2.63</b>
Technology Equipment GFJord Invest AS Total Technology Equipment	GFJord Invest AS Reg	32 500	0 <b>0</b>	0.00 <b>0.00</b>
Food & Beverages  Lumarine AS  Total Food & Beverages	Lumarine AS	4 130 211	2 083 053 <b>2 083 053</b>	0.69 <b>0.69</b>
Total shares			19 894 524	6.59
				3.33

# Holdings and positions (in SEK) as at 30 June 2023

Issuer	Security	Number/Nominal	Market value	% of total net assets
Futures contracts				_
Financial index				
Total financial index	OMX Stockholm 30 Index FUT 07/23 OMX	-300	442 500 <b>442 500</b>	0.15 <b>0.15</b>
Total futures contracts			442 500	0.15
Total other financial instruments			20 337 024	6.74
Total financial instruments			255 841 878	84.70
Other net assets/ liabilities			46 237 696	15.30
Total			302 079 574	100.00

<sup>\*</sup> Exposures by different types of financial assets against one and the same company or against companies in one and the same group

**Issuer** Bioservo Technology AB % total net assets 1.36

vo Technology AB

### **Management Company**

East Capital Asset Management S.A., a wholly-owned subsidiary of East Capital Holding AB Corporate identity number: B 136364, incorporated 29 January 2008 Share capital: EUR 1,000,000

Address: 11, rue Sainte-Zithe, L-2763 Luxembourg Phone: +352 27 860 701 Fax: +352 26684717

E-mail: luxembourg@eastcapital.com Internet: www.eastcapital.com

### **Board of the Management Company**

Karine Hirn, Chairperson of the Board Peter Elam Håkansson, Board Member Albin Rosengren, Board Member Paul Carr, Board Member (until 30.04.2023)

#### Senior management of the Management Company

Paul Carr, CEO (until 30.04.2023) Management Committee: Paul Carr, CEO and Conducting Officer (until 30.04.2023) Albin Rosengren, Conducting Officer (since 01.05.2023) Lucija Devetak, Conducting Officer (since 01.05.2023) Jean-Christophe Esteve, Conducting Officer (since 14.03.2023) Max Isaksson, Conducting Officer (until 03.01.2023) Kevin Wu, Conducting Officer

### Depositary

Skandinaviska Enskilda Banken (publ)

#### Supervisory authority

The Funds are authorised in Sweden and regulated by the Swedish Financial Supervisory Authority, Finansinspektionen. East Capital Asset Management S.A. is authorised in Luxembourg and regulated by the Luxembourg supervisory authority, *Commission de Surveillance du Secteur Financier* (CSSF).

### Legal Status of the Funds

The Fund Adrigo Small & Midcap L/S is a "Specialfond" pursuant to the Swedish Managers of Alternative Investment Funds Act (2013:561) ("LAIF"), which means that there are fewer investment restrictions compared to the standard mutual fund.

Mårten Asplund, Authorised public accountant KPMG AB. An agreement concerning the exchange of information and coordination has been entered into between the Funds' auditor and the Master Fund Company's auditor.

### Reporting principles

The Half Year report has been prepared in accordance with the Swedish Alternative Investment Fund Manager's Act (2013:561) and Finansinspektionen's regulation on alternative investment fund managers (FFFS 2013:10) and complies with the Swedish Investment Fund Association's guidelines where applicable.

